Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 29;26(1):122.
doi: 10.3390/molecules26010122.

Phloroglucinol Derivatives from Dryopteris crassirhizoma as Potent Xanthine Oxidase Inhibitors

Affiliations

Phloroglucinol Derivatives from Dryopteris crassirhizoma as Potent Xanthine Oxidase Inhibitors

Heung Joo Yuk et al. Molecules. .

Abstract

Dryopteris crassirhizoma rhizomes are used as a traditional medicine in Asia. The EtOAc extract of these roots has shown potent xanthine oxidase (XO) inhibitory activity. However, the main phloroglucinols in D. crassirhizoma rhizomes have not been analyzed. Thus, we investigated the major constituents responsible for this effect. Bioassay-guided purification isolated four compounds: flavaspidic acid AP (1), flavaspidic acid AB (2), flavaspidic acid PB (3), and flavaspidic acid BB (4). Among these, 1 showed the most potent inhibitory activity with a half-maximal inhibitory concentration (IC50) value of 6.3 µM, similar to that of allopurinol (IC50 = 5.7 µM) and better than that of oxypurinol (IC50 = 43.1 µM), which are XO inhibitors. A comparative activity screen indicated that the acetyl group at C3 and C3' is crucial for XO inhibition. For example, 1 showed nearly 4-fold higher efficacy than 4 (IC50 = 20.9 µM). Representative inhibitors (1-4) in the rhizomes of D. crassirhizoma showed reversible and noncompetitive inhibition toward XO. Furthermore, the potent inhibitors were shown to be present in high quantities in the rhizomes by a UPLC-QTOF-MS analysis. Therefore, the rhizomes of D. crassirhizoma could be used to develop nutraceuticals and medicines for the treatment of gout.

Keywords: Dryopteris crassirhizoma; flavaspidic acid; gout; phloroglucinols; traditional medicine; xanthine oxidase.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Chemical structures of isolated compounds 14 from rhizomes of Dryopteris crassirhizoma.
Figure 2
Figure 2
(a) Inhibitory effects of compounds 14 on the activity of xanthine oxidase (XO) based on the oxidation of xanthine to uric acid. (b) Catalytic activity of XO as a function of enzyme concentration at different concentrations of compound 1. (c) Lineweaver–Burk plots were constructed for the inhibition of XO by compound 1. The plot is expressed as 1/velocity versus 1/xanthine (S) with or without an inhibitor in the reaction solutions. (d) Dixon plots of XO inhibition by compound 1. The graphical symbols are substrate concentrations (50 μM, ●; 100 μM, ○; 200 μM, ▼).
Figure 3
Figure 3
Representative chromatograms of EtOAc rhizome extract of Dryopteris crassirhizoma. (a) Diode array detector (DAD) chromatogram and (b) total ion current-base peak intensity (TIC-BPI) chromatogram.
Figure 4
Figure 4
Negative ion mass spectrum acquired by UPLC-ESI/MS and MS/MS analysis of phloroglucinols (ad, 14, respectively) from rhizomes of Dryopteris crassirhizoma. Abbreviations: RF, residue of a fragment.

Similar articles

Cited by

References

    1. Gibson T. Hyperuricemia, gout and the kidney. Curr. Opin. Rheumatol. 2012;24:127–131. doi: 10.1097/BOR.0b013e32834f049f. - DOI - PubMed
    1. Bitik B., Öztürk M.A. An old disease with new insights: Update on diagnosis and treatment of gout. Eur. J. Rheumatol. 2014;1:72–77. doi: 10.5152/eurjrheumatol.2014.021. - DOI - PMC - PubMed
    1. Fan H., Zheng A., Xu P., Wang J., Xue T., Dai S., Pan S., Guo Y., Xie X., Li L., et al. High-protein diet induces hyperuricemia in a new animal model for studying human gout. Int. J. Mol. Sci. 2020;21:2147. doi: 10.3390/ijms21062147. - DOI - PMC - PubMed
    1. Fukunari A., Okamoto K., Nishino T.B., Eger T., Pai E.F., Kamezawa M., Yamada I., Kato N. Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: A potent xanthine oxidoreductase inhibitor with hepatic excretion. J. Pharmacol. Exp. Ther. 2004;311:519–528. doi: 10.1124/jpet.104.070433. - DOI - PubMed
    1. Martillo M.A., Nazzal L., Crittenden D.B. The crystallization of monosodium urate. Curr. Rheumatol. Rep. 2014;16:400. doi: 10.1007/s11926-013-0400-9. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources